MedPath

The efficacy of Fumaria parviflora L. versus gabapentin on pruritus of patients undergoing hemodialysis

Phase 3
Recruiting
Conditions
remic prururitus in dialysis patient.
Pruritus
Registration Number
IRCT20121031011341N11
Lead Sponsor
Shiraz University of Medical Sciences
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Recruiting
Sex
All
Target Recruitment
70
Inclusion Criteria

The hemodialysis patient who has uncontrollable pruritus and now at least 1 week doesn't use any antipruritus medication
who had pruritus for at least 6 weeks
patient must have normal range phosphor and potassium in the past month
Parathyroid Hormone (PTH) must be lower than 500
measured visual analogue scale (VAS) score must be four or more

Exclusion Criteria

They do not have liver disease, a history of convulsions, or a specific skin disease that causes itching, and they do not have hemolytic blood disease.
Patients who complain of itching for the first time are not included in the study
If the patient was taking medication that interacted with gabapentin or Fumaria parviflora L., he was not included in the study
Those who are allergic to Fumaria parviflora L. or Gabapentin are not included in the study

Study & Design

Study Type
interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Itching score in the 5-D pruritus questionnaire. Timepoint: Before the start of the intervention (the beginning of the study) and two months later (the end of the study). Method of measurement: 5D itch questionnaire.
Secondary Outcome Measures
NameTimeMethod
Quality of life score in DLQI questionnaire. Timepoint: Before the start of the intervention (the beginning of the study) and two months later (the end of the study). Method of measurement: DLQI quality of life questionnaire.
© Copyright 2025. All Rights Reserved by MedPath